Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 56

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 56
---
49:215–231.                                                                                               |

| 18 | Aguilar-Guisado                                                                        
 et al Clin Transplant 2011;25:E629–38; Mace et al MMWR 202;70:1–35. 19                 
 Queener et al JID 1997;165:764-768; Dow and Smith New Microb New Infect 2022;45:100964 |

| 20 | https://www.ecdc.europa.eu/en/dengue-monthly#:~:text=This%20is%20an%20increase%20of%2032%20653%20cases% 
 20and%2032,853%20deaths%20have%20been%20reported.                                                       |

| 21 | https://www.cdc.gov/rsv/php/surveillance/index.html#cdc_survey_profile_surveys_used-rsv-burden-estimates.                            
 22 In 2014, we signed a cooperative research and development agreement with the United States Army Medical and Materiel Development  
 Activity (Agreement W81XWH-14-0313). Under this agreement, we agreed to submit an NDA for Tafenoquine to the FDA (as Arakoda), while 
 the US Army agreed to finance the bulk of the necessary development activities in support of that goal.                              |

| 23 | Zottig                                       
 et al Military Medicine 2020; 185 (S1): 687. |

<div align='center'>4</div>

The FDA and Australia’s medicinal regulatory agency, the Therapeutic Goods Administration, subsequently approved Arakoda (brand name in the U.S.) and Kodatef (brand name in Australia), respectively, for prevention of malaria in travelers in 2018. Prescribing information and guidance for patients can be found at www.arakoda.com. The features and benefits of Tafenoquine for malaria prophylaxis, some of which have been noted by third-party experts, include: convenient once weekly dosing following a three day load; the absence of reports of drug resistance during malaria prophylaxis; activity against liver and blood stages of malaria as well as both the major malaria species ( Plasmodium vivaxand Plasmodium falciparum); absence of any black-box safety warnings; good tolerability, including in women and individuals with prior psychiatric medical history; and a comparable adverse event rate to placebo with up to 12 months continuous dosing.